^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Androgen receptor inhibitor

    Related drugs:
    1d
    Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=52, Recruiting, Weill Medical College of Cornell University | Active, not recruiting --> Recruiting | N=37 --> 52
    Enrollment open • Enrollment change
    |
    CELLSEARCH®
    |
    Keytruda (pembrolizumab) • Xtandi (enzalutamide) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    2d
    DARE: An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment (clinicaltrials.gov)
    P=N/A, N=800, Not yet recruiting, Bayer
    New trial • Real-world evidence
    |
    Nubeqa (darolutamide) • bicalutamide
    2d
    Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial (clinicaltrials.gov)
    P2, N=532, Recruiting, Mayo Clinic | Trial completion date: May 2029 --> Feb 2031 | Trial primary completion date: May 2029 --> Feb 2031
    Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • abiraterone acetate • Nubeqa (darolutamide) • apalutamide • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
    3d
    Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART) (2024-511140-37-00)
    P1/2, N=140, Completed, Universitair Ziekenhuis Gent | Active, not recruiting --> Completed
    Trial completion
    |
    FOLH1 positive
    |
    Nubeqa (darolutamide)
    7d
    TARA: An Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in Australia (clinicaltrials.gov)
    P=N/A, N=1000, Recruiting, Bayer | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    abiraterone acetate
    7d
    ARAMIS Rollover: Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer (clinicaltrials.gov)
    P3, N=402, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Nubeqa (darolutamide)
    8d
    WTAP stabilized by USP7 contributes to enzalutamide resistance in prostate cancer via mediating AKT m6A-modification. (PubMed, Cancer Gene Ther)
    Mechanistically, ubiquitin-specific protease (USP7) enhanced the stability of WTAP by the ubiquitin-proteasome pathway in ENZR cells, thereby WTAP increases promote AKT signaling through an m6A-mediated way, and an AKT inhibitor can abolish the pro-resistance phenotype mediated by WTAP. Together, these findings suggest that WTAP plays a key role in ENZR development of PCa cells, and WTAP may be a potential treatment target for ENZR tumors.
    Journal
    |
    WT1 (WT1 Transcription Factor) • USP7 (Ubiquitin Specific Peptidase 7) • WTAP (WT1 Associated Protein)
    |
    Xtandi (enzalutamide)
    8d
    Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study (clinicaltrials.gov)
    P2, N=8, Active, not recruiting, University of Washington | Trial completion date: Apr 2026 --> Apr 2027
    Trial completion date
    |
    apalutamide • Simponi (golimumab)
    8d
    A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described (clinicaltrials.gov)
    P=N/A, N=805, Active, not recruiting, Bayer | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial primary completion date
    |
    Nubeqa (darolutamide)
    9d
    Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=39, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Jan 2030 --> Jun 2030 | Trial primary completion date: Jan 2028 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • Jakafi (ruxolitinib)
    11d
    The prognostic value of the CALLY index in patients with metastatic hormone-sensitive prostate cancer. (PubMed, World J Urol)
    The CALLY index is an accessible and independent prognostic biomarker for OS and CRPC progression in mHSPC. Its integration into clinical assessment could enhance risk stratification and support personalized treatment planning, potentially improving long-term patient outcomes.
    Retrospective data • Journal
    |
    CRP (C-reactive protein)
    |
    bicalutamide